AU2001262153A1 - Pyrrole-2,5-dione derivatives for the treatment of diabetes - Google Patents

Pyrrole-2,5-dione derivatives for the treatment of diabetes

Info

Publication number
AU2001262153A1
AU2001262153A1 AU2001262153A AU6215301A AU2001262153A1 AU 2001262153 A1 AU2001262153 A1 AU 2001262153A1 AU 2001262153 A AU2001262153 A AU 2001262153A AU 6215301 A AU6215301 A AU 6215301A AU 2001262153 A1 AU2001262153 A1 AU 2001262153A1
Authority
AU
Australia
Prior art keywords
pyrrole
diabetes
treatment
dione derivatives
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262153A
Inventor
David Haigh
Brian Peter Slingsby
David Glynn Smith
Robert William Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2001262153A1 publication Critical patent/AU2001262153A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AU2001262153A 2000-04-04 2001-04-02 Pyrrole-2,5-dione derivatives for the treatment of diabetes Abandoned AU2001262153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0008264 2000-04-04
GBGB0008264.4A GB0008264D0 (en) 2000-04-04 2000-04-04 Novel method and compounds
PCT/EP2001/003687 WO2001074771A1 (en) 2000-04-04 2001-04-02 Pyrrole-2,5-dione derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
AU2001262153A1 true AU2001262153A1 (en) 2001-10-15

Family

ID=9889171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262153A Abandoned AU2001262153A1 (en) 2000-04-04 2001-04-02 Pyrrole-2,5-dione derivatives for the treatment of diabetes

Country Status (3)

Country Link
AU (1) AU2001262153A1 (en)
GB (1) GB0008264D0 (en)
WO (1) WO2001074771A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
CA2455753A1 (en) * 2001-08-03 2003-02-13 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
JP2005525362A (en) * 2002-03-01 2005-08-25 カイロン コーポレイション Methods and compositions for the treatment of ischemia
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
EP1603883B1 (en) 2003-02-03 2012-03-28 Janssen Pharmaceutica NV Quinoline-derived amide modulators of vanilloid vr1 receptor
FR2850967B1 (en) * 2003-02-12 2007-04-13 Galderma Res & Dev NOVEL MODULATING COMPOUNDS OF PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
CA2512766A1 (en) * 2003-02-12 2004-08-26 Galderma Research & Development, S.N.C. Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
DE102004010194A1 (en) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-one derivatives, their preparation and use in medicaments
JP4875978B2 (en) * 2004-03-15 2012-02-15 武田薬品工業株式会社 Aminophenylpropanoic acid derivatives
US20070249670A1 (en) * 2004-11-09 2007-10-25 Smithkline Beecham Corporation Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof
CA2592771A1 (en) * 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500058D0 (en) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
SE0500056D0 (en) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
EP1838685A4 (en) * 2005-01-10 2010-01-27 Astrazeneca Ab Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
SE0500055D0 (en) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ATE533485T1 (en) 2005-10-31 2011-12-15 Merck Sharp & Dohme CETP INHIBITORS
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
RS52626B (en) * 2006-07-25 2013-06-28 Cephalon Inc. Pyridizinone derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20110112193A1 (en) * 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2638036B1 (en) * 2010-11-09 2017-08-16 Betta Pharmaceuticals Co., Ltd. Compound for increasing kinase active and application thereof
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CA3131805C (en) * 2019-03-01 2023-11-21 Ac Immune Sa Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
MX2022001863A (en) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors.
TW202122082A (en) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
LT4084778T (en) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340263A (en) * 1964-02-14 1967-09-05 Ciba Geigy Corp Amino-pyrroles
CZ280738B6 (en) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituted pyrroles, their use for preparing medicaments and medicaments based thereon
DE4005970A1 (en) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh NEW TRISUBSTITUTED MALEINIMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE69911935T3 (en) * 1998-03-13 2008-02-07 The University Of British Columbia, Vancouver GRANULATIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER
DE69919707T2 (en) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
WO2000006564A1 (en) * 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
EP1119548B1 (en) * 1998-10-08 2004-12-08 SmithKline Beecham plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)

Also Published As

Publication number Publication date
WO2001074771A1 (en) 2001-10-11
GB0008264D0 (en) 2000-05-24

Similar Documents

Publication Publication Date Title
AU2001262153A1 (en) Pyrrole-2,5-dione derivatives for the treatment of diabetes
AU5722800A (en) Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
AU2001231104A1 (en) Methods for treating diabetes
AU2000276362A1 (en) Composition for the treatment of diabetes
AU1246101A (en) Set for blood processing
HK1038564A1 (en) Pyrrole-2,5-diones as gsk-3 inhibitors
MXPA02008801A (en) Indole derivatives, process for preparation of the same and use thereof.
AU2002212745A1 (en) Cyanopyrrolidine derivatives
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
HK1047588A1 (en) 2-Amino-4H-3,1-benzoxazine-4-one derivatives for the treatment of obesity
AU2001292480A1 (en) Novel pyridazine compounds for the treatment of diabetes
AU5844300A (en) Eugenia jambolina fruit extracts for treating diabetes
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU4139600A (en) 1,3-dipolar cycloadditions to polypyrrolic macrocycles
AU2001241056A1 (en) Spiro compounds, process for preparing the same and use thereof as drugs
AU773240C (en) Medicament for treating hypertension
AU2001259285A1 (en) Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU2001294673A1 (en) Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
AU5426500A (en) Benzazepine derivatives, process for the preparation of the same and uses thereof
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
AU2001258841A1 (en) Heterocyclic compounds
AU2001275794A1 (en) Pyrrole derivatives
AU2002218400A1 (en) 3-substituted 2,7-naphthyridin-1-yl derivatives
AU2001286188A1 (en) Tricyclic heterocyclic compound, process for producing the same, and use thereof